In the past two decades, structural and functional neuroimaging findings have greatly
modified longstanding notions regarding the pathophysiology of amyotrophic lateral …

To be fully prepared for the emergence of neuroprotective drugs in amyotrophic lateral
sclerosis (ALS), there is a clear need for the development of robust biomarkers for disease …

Introduction: Several neuroimaging techniques have been used to define in vivo markers of
pathological alterations underlying amyotrophic lateral sclerosis (ALS). Growing evidence …

In patients with ALS, conventional MR imaging is frequently noninformative, and its use has
been restricted to excluding other conditions that can mimic ALS. Conversely, the extensive …

MRI and PET studies in ALS have consistently shown patterns of functional and structural
changes considered to be the pathological signature of the disease. The constant advance …

Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disease for which a precise
cause has not yet been identified. Standard CT or MRI evaluation does not demonstrate …

Amyotrophic lateral sclerosis (ALS; motor neuron disease) is a relentlessly progressive
disorder. After half a century of trials, only one drug with modest disease-modifying potency …

The diagnosis of amyotrophic lateral sclerosis can be challenging due to its heterogeneity in
clinical presentation and overlap with other neurological disorders. Diagnosis early in the …

Amyotrophic lateral sclerosis (ALS) is now recognised to be a heterogeneous
neurodegenerative syndrome of the motor system and its frontotemporal cortical …

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative, clinically
heterogeneous syndrome pathologically overlapping with frontotemporal dementia. To date …